RNA mediated Toll-like receptor stimulation in health and disease

RNA Biology

Volumn 9, Issue 6, 2012, Pages 828-842

  Dalpke, Alexander H ^a   Helm, Mark ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Autoimmunity; Infections; Innate immunity; Modifications; Nucleic acids; Toll like receptor

Indexed keywords

ALPHA INTERFERON; BACTERIAL RNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; MYELOID DIFFERENTIATION FACTOR 88; NUCLEIC ACID; OLIGOMER; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CYTOKINE RELEASE; DISEASES; HEALTH; INNATE IMMUNITY; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN RNA BINDING; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TRAFFIC;

BACTERIA (MICROORGANISMS);

EID: 84863496034     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.20206     Document Type: Review

References (189)

1. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411:494-8; PMID:11373684; http://dx.doi.org/10.1038/ 35078107.
2. Schlee M, Hornung V, Hartmann G. siRNA and isRNA: two edges of one sword. Mol Ther 2006; 14:463-70; PMID:16877044; http://dx.doi.org/10.1016/j.ymthe. 2006.06.001.
3. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86:973-83; PMID:8808632; http://dx.doi.org/10.1016/S0092-8674(00)80172-5.
4. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282:2085-8; PMID:9851930; http://dx.doi.org/10.1126/science. 282.5396.2085.
5. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137:1142-62; PMID:4573839; http://dx.doi.org/10.1084/jem.137.5.1142.
6. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989; 54:1-13; PMID:2700931; http://dx.doi.org/10.1101/SQB.1989.054.01.003.
7. Medzhitov R. Approaching the asymptote: 20 years later. Immunity 2009; 30:766-75; PMID:19538928; http://dx.doi.org/10.1016/j.immuni.2009.06.004.
8. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11:373-84; PMID:20404851; http://dx.doi.org/10.1038/ni.1863.
9. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394-7; PMID:9237759; http://dx.doi.org/10.1038/41131.
10. Yang RB, Mark MR, Gray A, Huang A, Xie MH, Zhang M, et al. Toll-like receptor-2 mediates lipo-polysaccharide-induced cellular signalling. Nature 1998; 395:284-8; PMID:9751057; http://dx.doi.org/10.1038/26239.
11. Kirschning CJ, Wesche H, Merrill Ayres T, Rothe M. Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. J Exp Med 1998; 188:2091-7; PMID:9841923; http://dx.doi.org/10.1084/jem.188.11.2091.
12. Inohara N, Koseki T, del Peso L, Hu Y, Yee C, Chen S, et al. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factorkappaB. J Biol Chem 1999; 274:14560-7; PMID:10329646; http://dx.doi.org/10.1074/jbc.274.21.14560.
13. Bertin J, Nir WJ, Fischer CM, Tayber OV, Errada PR, Grant JR, et al. Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that activates NFkappaB. J Biol Chem 1999; 274:12955-8; PMID:10224040; http://dx.doi.org/10.1074/jbc.274.19.12955.
14. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278:8869-72; PMID:12527755; http://dx.doi.org/10. 1074/jbc.C200651200.
15. Brown GD, Gordon S. Immune recognition. A new receptor for beta-glucans. Nature 2001; 413:36-7; PMID:11544516; http://dx.doi.org/10.1038/35092620.
16. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5:730-7; PMID:15208624; http://dx.doi.org/10.1038/ni1087.
17. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441:101-5; PMID:16625202; http://dx.doi.org/10.1038/ nature04734.
18. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10:417-26; PMID:12191486; http://dx.doi.org/10.1016/S1097-2765(02) 00599-3.
19. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009; 458:514-8; PMID:19158675; http://dx.doi.org/10.1038/nature07725.
20. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009; 458:509-13; PMID:19158676; http://dx.doi.org/10.1038/nature07710.
21. Bürckstümmer T, Baumann C, Blüml S, Dixit E, Dürnberger G, Jahn H, et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 2009; 10:266-72; PMID:19158679; http://dx.doi.org/10.1038/ni.1702.
22. Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: first line of the immune response to cell stress. Cell 2006; 126:659-62; PMID:16923387; http://dx.doi.org/10.1016/j.cell.2006.08.002.
23. Dangl JL, Jones JD. Plant pathogens and integrated defence responses to infection. Nature 2001; 411:826-33; PMID:11459065; http://dx.doi.org/10.1038/ 35081161.
24. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7:353-64; PMID:17457343; http://dx.doi.org/10.1038/nri2079.
25. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34:637-50; PMID:21616434; http://dx.doi.org/10.1016/j.immuni.2011.05.006.
26. Nish S, Medzhitov R. Host defense pathways: role of redundancy and compensation in infectious disease phenotypes. Immunity 2011; 34:629-36; PMID:21616433; http://dx.doi.org/10.1016/j.immuni.2011.05.009.
27. Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol 2009; 9:535-42; PMID:19556980; http://dx.doi.org/10.1038/nri2587.
28. Pasare C, Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 2005; 438:364-8; PMID:16292312; http://dx.doi.org/10.1038/ nature04267.
29. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001; 2:947-50; PMID:11547333; http://dx.doi.org/10.1038/ni712.
30. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011; 470:543-7; PMID:21350488; http://dx.doi.org/10.1038/ nature09737.
31. Deane JA, Bolland S. Nucleic acid-sensing TLRs as modifiers of autoimmunity. J Immunol 2006; 177:6573-8; PMID:17082566.
32. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NFkappaB by Toll-like receptor 3. Nature 2001; 413:732-8; PMID:11607032; http://dx.doi.org/10.1038/35099560.
33. de Bouteiller O, Merck E, Hasan UA, Hubac S, Benguigui B, Trinchieri G, et al. Recognition of double-stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J Biol Chem 2005; 280:38133-45; PMID:16144834; http://dx.doi.org/10.1074/jbc. M507163200.
34. Matsumoto M, Funami K, Tanabe M, Oshiumi H, Shingai M, Seto Y, et al. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 2003; 171:3154-62; PMID:12960343.
35. Nishiya T, DeFranco AL. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. J Biol Chem 2004; 279:19008-17; PMID:14976215; http://dx.doi.org/10.1074/jbc.M311618200.
36. Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM, et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 2008; 320:379-81; PMID:18420935; http://dx.doi.org/10.1126/science. 1155406.
37. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009; 458:1191-5; PMID:19252480; http://dx.doi.org/10.1038/nature07830.
38. Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007; 130:1071-82; PMID:17889651; http://dx.doi.org/10.1016/j.cell.2007.09. 008.
39. Leonard JN, Ghirlando R, Askins J, Bell JK, Margulies DH, Davies DR, et al. The TLR3 signaling complex forms by cooperative receptor dimerization. Proc Natl Acad Sci USA 2008; 105:258-63; PMID:18172197; http://dx.doi.org/10.1073/ pnas.0710779105.
40. Fukuda K, Watanabe T, Tokisue T, Tsujita T, Nishikawa S, Hasegawa T, et al. Modulation of double-stranded RNA recognition by the N-terminal histidine-rich region of the human toll-like receptor 3. J Biol Chem 2008; 283:22787-94; PMID:18544529; http://dx.doi.org/10.1074/jbc.M802284200.
41. Pirher N, Ivicak K, Pohar J, Bencina M, Jerala R. A second binding site for double-stranded RNA in TLR3 and consequences for interferon activation. Nat Struct Mol Biol 2008; 15:761-3; PMID:18568036; http://dx.doi.org/10.1038/nsmb. 1453.
42. Avril T, de Tayrac M, Leberre C, Quillien V. Not all polyriboinosinic- polyribocytidylic acids (Poly I:C) are equivalent for inducing maturation of dendritic cells: implication for alpha-type-1 polarized DCs. J Immunother 2009; 32:353-62; PMID:19342970; http://dx.doi.org/10.1097/CJI.0b013e31819d29bf.
43. Karikó K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004; 279:12542-50; PMID:14729660; http://dx.doi.org/10.1074/jbc.M310175200.
44. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303:1526-9; PMID:14976262; http://dx.doi.org/10.1126/ science.1093620.
45. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303:1529-31; PMID:14976261; http://dx.doi.org/10.1126/science.1093616.
46. Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005; 23:165-75; PMID:16111635; http://dx.doi.org/10.1016/j.immuni.2005.06.008.
47. Diken M, Kreiter S, Selmi A, Britten CM, Huber C, Türeci O, et al. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther 2011; 18:702-8; PMID:21368901; http://dx.doi.org/10.1038/gt.2011.17.
48. Eberle F, Giessler K, Deck C, Heeg K, Peter M, Richert C, et al. Modifications in small interfering RNA that separate immunostimulation from RNA interference. J Immunol 2008; 180:3229-37; PMID:18292547.
49. Gehrig S, Eberle ME, Botschen F, Rimbach K, Eberle F, Eigenbrod T, et al. Identification of modifications in microbial, native tRNA that suppress immunostimulatory activity. J Exp Med 2012; 209:225-33; PMID:22312113; http://dx.doi.org/10.1084/jem.20111044.
50. Jöckel S, Nees G, Sommer R, Zhao Y, Cherkasov D, Hori H, et al. The 2′-O-methylation status of a single guanosine controls transfer RNA-mediated Toll-like receptor 7 activation or inhibition. J Exp Med 2012; 209:235-41; PMID:22312111; http://dx.doi.org/10.1084/jem.20111075.
51. Gantier MP, Tong S, Behlke MA, Xu D, Phipps S, Foster PS, et al. TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human macrophages. J Immunol 2008; 180:2117-24; PMID:18250417.
52. Diebold SS, Massacrier C, Akira S, Paturel C, Morel Y, Reis e Sousa C. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur J Immunol 2006; 36:3256-67; PMID:17111347; http://dx.doi.org/10.1002/eji.200636617.
53. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, et al. Sequence-specific potent induction of IFNalpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11:263-70; PMID:15723075; http://dx.doi.org/10.1038/nm1191.
54. Forsbach A, Nemorin JG, Völp K, Samulowitz U, Montino C, Müller C, et al. Characterization of conserved viral leader RNA sequences that stimulate innate immunity through TLRs. Oligonucleotides 2007; 17:405-17; PMID:18072859; http://dx.doi.org/10.1089/oli.2007.0098.
55. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 2004; 101:5598-603; PMID:15034168; http://dx.doi.org/10.1073/pnas. 0400937101.
56. Eberle F, Sirin M, Binder M, Dalpke AH. Bacterial RNA is recognized by different sets of immunoreceptors. Eur J Immunol 2009; 39:2537-47; PMID:19662634; http://dx.doi.org/10.1002/eji.200838978.
57. Mancuso G, Gambuzza M, Midiri A, Biondo C, Papasergi S, Akira S, et al. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat Immunol 2009; 10:587-94; PMID:19430477; http://dx.doi.org/10.1038/ni.1733.
58. Wei T, Gong J, Jamitzky F, Heckl WM, Stark RW, Rössle SC. Homology modeling of human Toll-like receptors TLR7, 8 and 9 ligand-binding domains. Protein Sci 2009; 18:1684-91; PMID:19521997; http://dx.doi.org/10.1002/pro.186.
59. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002; 3:499; PMID:12032557; http://dx.doi.org/10.1038/ni0602- 499.
60. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3:196-200; PMID:11812998; http://dx.doi.org/10.1038/ni758.
61. Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA 2003; 100:6646-51; PMID:12738885; http://dx.doi.org/10.1073/pnas.0631696100.
62. Forsbach A, Samulowitz U, Völp K, Hofmann HP, Noll B, Tluk S, et al. Dual or triple activation of TLR7, TLR8 and/or TLR9 by single-stranded oligoribonucleotides. Nucleic Acid Ther 2011; 21:423-36; PMID:22196370; http://dx.doi.org/10.1089/nat.2011.0323.
63. Lan T, Putta MR, Wang D, Dai M, Yu D, Kandimalla ER, et al. Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8. Biochem Biophys Res Commun 2009; 386:443-8; PMID:19523922; http://dx.doi.org/10.1016/j.bbrc.2009.06.036.
64. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-5; PMID:11130078; http://dx.doi.org/10.1038/35047123.
65. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol 1999; 73:329-68; PMID:10399010; http://dx.doi.org/10.1016/ S0065-2776(08)60790-7.
66. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374:546-9; PMID:7700380; http://dx.doi.org/10.1038/374546a0.
67. Haas T, Metzger J, Schmitz F, Heit A, Müller T, Latz E, et al. The DNA sugar backbone 2′ deoxyribose determines toll-like receptor 9 activation. Immunity 2008; 28:315-23; PMID:18342006; http://dx.doi.org/10.1016/ j.immuni.2008.01.013.
68. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004; 5:190-8; PMID:14716310; http://dx.doi.org/10.1038/ni1028.
69. Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol 2006; 7:49-56; PMID:16341217; http://dx.doi.org/10.1038/ni1280.
70. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, Möröy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 2000; 25:177-81; PMID:10835632; http://dx.doi.org/10.1038/76032.
71. Yasutomo K, Horiuchi T, Kagami S, Tsukamoto H, Hashimura C, Urushihara M, et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet 2001; 28:313-4; PMID:11479590; http://dx.doi.org/10.1038/91070.
72. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416:603-7; PMID:11948342; http://dx.doi.org/10.1038/416603a.
73. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005; 202:321-31; PMID:16027240; http://dx.doi.org/10. 1084/jem.20050338.
74. Peter ME, Kubarenko AV, Weber AN, Dalpke AH. Identification of an N-terminal recognition site in TLR9 that contributes to CpG-DNA-mediated receptor activation. J Immunol 2009; 182:7690-7; PMID:19494293; http://dx.doi.org/10.4049/jimmunol.0900819.
75. Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi GP, Chapman HA, et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008; 456:658-62; PMID:18820679; http://dx.doi.org/10.1038/nature07405.
76. Park B, Brinkmann MM, Spooner E, Lee CC, Kim YM, Ploegh HL. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat Immunol 2008; 9:1407-14; PMID:18931679; http://dx.doi.org/10. 1038/ni.1669.
77. Li Y, Berke IC, Modis Y. DNA binding to proteolytically activated TLR9 is sequence-independent and enhanced by DNA curvature. EMBO J 2011; 31:919-31; PMID:22258621; http://dx.doi.org/10.1038/emboj.2011.441.
78. Kowalinski E, Lunardi T, McCarthy AA, Louber J, Brunel J, Grigorov B, et al. Structural basis for the activation of innate immune pattern-recognition receptor RIG-I by viral RNA. Cell 2011; 147:423-35; PMID:22000019; http://dx.doi.org/10.1016/j.cell.2011.09.039.
79. Luo D, Ding SC, Vela A, Kohlway A, Lindenbach BD, Pyle AM. Structural insights into RNA recognition by RIG-I. Cell 2011; 147:409-22; PMID:22000018; http://dx.doi.org/10.1016/j.cell.2011.09.023.
80. Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, et al. 5′-Triphosphate RNA is the ligand for RIG-I. Science 2006; 314:994-7; PMID:17038590; http://dx.doi.org/10.1126/science.1132505.
81. Binder M, Eberle F, Seitz S, Mücke N, Hüber CM, Kiani N, et al. Molecular mechanism of signal perception and integration by the innate immune sensor retinoic acid-inducible gene-I (RIG-I). J Biol Chem 2011; 286:27278-87; PMID:21659521; http://dx.doi.org/10.1074/jbc.M111.256974.
82. Roberts TL, Idris A, Dunn JA, Kelly GM, Burnton CM, Hodgson S, et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 2009; 323:1057-60; PMID:19131592; http://dx.doi.org/10.1126/ science.1169841.
83. Unterholzner L, Keating SE, Baran M, Horan KA, Jensen SB, Sharma S, et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol 2010; 11:997-1004; PMID:20890285; http://dx.doi.org/10.1038/ni.1932.
84. Sharma S, DeOliveira RB, Kalantari P, Parroche P, Goutagny N, Jiang Z, et al. Innate immune recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genome. Immunity 2011; 35:194-207; PMID:21820332; http://dx.doi.org/10.1016/j.immuni.2011.05.016.
85. Tabeta K, Hoebe K, Janssen EM, Du X, Georgel P, Crozat K, et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol 2006; 7:156-64; PMID:16415873; http://dx.doi.org/10.1038/ni1297.
86. Yanai H, Ban T, Wang Z, Choi MK, Kawamura T, Negishi H, et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 2009; 462:99-103; PMID:19890330; http://dx.doi.org/10.1038/ nature08512.
87. Kim YM, Brinkmann MM, Paquet ME, Ploegh HL. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature 2008; 452:234-8; PMID:18305481; http://dx.doi.org/10.1038/nature06726.
88. Fukui R, Saitoh S, Matsumoto F, Kozuka-Hata H, Oyama M, Tabeta K, et al. Unc93B1 biases Toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing. J Exp Med 2009; 206:1339-50; PMID:19451267; http://dx.doi.org/10.1084/jem.20082316.
89. Melo MB, Kasperkovitz P, Cerny A, Könen-Waisman S, Kurt-Jones EA, Lien E, et al. UNC93B1 mediates host resistance to infection with Toxoplasma gondii. PLoS Pathog 2010; 6:1001071; PMID:20865117; http://dx.doi.org/10.1371/ journal.ppat.1001071.
90. Deshmukh SD, Kremer B, Freudenberg M, Bauer S, Golenbock DT, Henneke P. Macrophages recognize streptococci through bacterial single-stranded RNA. EMBO Rep 2011; 12:71-6; PMID:21164516; http://dx.doi.org/10.1038/embor.2010.189.
91. Casrouge A, Zhang SY, Eidenschenk C, Jouanguy E, Puel A, Yang K, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006; 314:308-12; PMID:16973841; http://dx.doi.org/10.1126/science.1128346.
92. Ewald SE, Engel A, Lee J, Wang M, Bogyo M, Barton GM. Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase. J Exp Med 2011; 208:643-51; PMID:21402738; http://dx.doi.org/10.1084/jem.20100682.
93. Sepulveda FE, Maschalidi S, Colisson R, Heslop L, Ghirelli C, Sakka E, et al. Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. Immunity 2009; 31:737-48; PMID:19879164; http://dx.doi.org/10.1016/j.immuni.2009.09.013.
94. Baumann CL, Aspalter IM, Sharif O, Pichlmair A, Blüml S, Grebien F, et al. CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med 2010; 207:2689-701; PMID:21078886; http://dx.doi.org/10.1084/jem.20101111.
95. Koski GK, Karikó K, Xu S, Weissman D, Cohen PA, Czerniecki BJ. Cutting edge: innate immune system discriminates between RNA containing bacterial versus eukaryotic structural features that prime for high-level IL-12 secretion by dendritic cells. J Immunol 2004; 172:3989-93; PMID:15034009.
96. Cantara WA, Crain PF, Rozenski J, McCloskey JA, Harris KA, Zhang X, et al. The RNA Modification Database, RNAMDB: 2011 update. Nucleic Acids Res 2011; 39:195-201; PMID:21071406; http://dx.doi.org/10.1093/nar/gkq1028.
97. Anderson BR, Muramatsu H, Jha BK, Silverman RH, Weissman D, Karikó K. Nucleoside modifications in RNA limit activation of 2′-5′- oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res 2011; 39:9329-38; PMID:21813458; http://dx.doi.org/10.1093/ nar/gkr586.
98. Anderson BR, Muramatsu H, Nallagatla SR, Bevilacqua PC, Sansing LH, Weissman D, et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res 2010; 38:5884-92; PMID:20457754; http://dx.doi.org/10.1093/nar/gkq347.
99. Robbins M, Judge A, Liang L, McClintock K, Yaworski E, MacLachlan I. 2′-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther 2007; 15:1663-9; PMID:17579574; http://dx.doi.org/10.1038/sj.mt.6300240.
100. Sioud M, Furset G, Cekaite L. Suppression of immunostimulatory siRNA-driven innate immune activation by 2′-modified RNAs. Biochem Biophys Res Commun 2007; 361:122-6; PMID:17658482; http://dx.doi.org/10.1016/j.bbrc. 2007.06.177.
101. De Clercq E, Zmudzka B, Shugar D. Antiviral activity of polynucleotides: role of the 2′-hydroxyl and a pyrimidine-5-methyl. FEBS Lett 1972; 24:137-40; PMID:4343812; http://dx.doi.org/10.1016/0014-5793(72)80845-7.
102. Lacoux C, Di Marino D, Pilo Boyl P, Zalfa F, Yan B, Ciotti MT, et al. BC1-FMRP interaction is modulated by 2′-O-methylation: RNA-binding activity of the tudor domain and translational regulation at synapses. Nucleic Acids Res 2012; In press; PMID:22238374; http://dx.doi.org/10.1093/nar/gkr1254.
103. Motorin Y, Helm M. RNA nucleotide methylation. Wiley Interdiscip Rev RNA 2011; 2:611-31; PMID:21823225; http://dx.doi.org/10.1002/wrna.79.
104. Jühling F, Mörl M, Hartmann RK, Sprinzl M, Stadler PF, Pütz J. tRNAdb 2009: compilation of tRNA sequences and tRNA genes. Nucleic Acids Res 2009; 37:159-62; PMID:18957446; http://dx.doi.org/10.1093/nar/gkn772.
105. Czerwoniec A, Dunin-Horkawicz S, Purta E, Kaminska KH, Kasprzak JM, Bujnicki JM, et al. MODOMICS: a database of RNA modification pathways. 2008 update. Nucleic Acids Res 2009; 37:118-21; PMID:18854352; http://dx.doi.org/10. 1093/nar/gkn710.
106. Kreiter S, Diken M, Selmi A, Türeci O, Sahin U. Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol 2011; 23:399-406; PMID:21497074; http://dx.doi.org/10.1016/j.coi.2011.03.007.
107. Karikó K, Weissman D. Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development. Curr Opin Drug Discov Devel 2007; 10:523-32; PMID:17786850.
108. Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R, et al. A status report on RNAi therapeutics. Silence 2010; 1:14; PMID:20615220; http://dx.doi.org/10.1186/1758-907X-1-14.
109. Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol 2012; 19:60-71; PMID:22284355; http://dx.doi.org/10.1016/ j.chembiol.2011.12.008.
110. Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, van Gils JM, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011; 478:404-7; PMID:22012398; http://dx.doi.org/10. 1038/nature10486.
111. Elmén J, Lindow M, Schütz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452:896-9; PMID:18368051; http://dx.doi.org/10.1038/nature06783.
112. Watts JK, Deleavey GF, Damha MJ. Chemically modified siRNA: tools and applications. Drug Discov Today 2008; 13:842-55; PMID:18614389; http://dx.doi.org/10.1016/j.drudis.2008.05.007.
113. Deleavey GF, Watts JK, Alain T, Robert F, Kalota A, Aishwarya V, et al. Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing. Nucleic Acids Res 2010; 38:4547-57; PMID:20413581; http://dx.doi.org/10.1093/nar/gkq181.
114. Zhou X, He X, Liang J, Li A, Xu T, Kieser T, et al. A novel DNA modification by sulphur. Mol Microbiol 2005; 57:1428-38; PMID:16102010; http://dx.doi.org/10.1111/j.1365-2958.2005.04764.x.
115. Eckstein F. Phosphorothioation of DNA in bacteria. Nat Chem Biol 2007; 3:689-90; PMID:17948013; http://dx.doi.org/10.1038/nchembio1107-689.
116. Wang L, Chen S, Xu T, Taghizadeh K, Wishnok JS, Zhou X, et al. Phosphorothioation of DNA in bacteria by dnd genes. Nat Chem Biol 2007; 3:709-10; PMID:17934475; http://dx.doi.org/10.1038/nchembio.2007.39.
117. Detzer A, Sczakiel G. Phosphorothioate-stimulated uptake of siRNA by mammalian cells: a novel route for delivery. Curr Top Med Chem 2009; 9:1109-16; PMID:19860711; http://dx.doi.org/10.2174/156802609789630884.
118. Dalpke AH, Zimmermann S, Albrecht I, Heeg K. Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology 2002; 106:102-12; PMID:11972638; http://dx.doi.org/10.1046/j.1365-2567.2002.01410.x.
119. Lan T, Dai M, Wang D, Zhu FG, Kandimalla ER, Agrawal S. Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies. J Med Chem 2009; 52:6871-9; PMID:19824640; http://dx.doi.org/10.1021/jm901145s.
120. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdörfer B, Giese T, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168:4531-7; PMID:11970999.
121. Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol 1997; 27:2340-4; PMID:9341778; http://dx.doi.org/10.1002/eji.1830270931.
122. Kerkmann M, Rothenfusser S, Hornung V, Towarowski A, Wagner M, Sarris A, et al. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol 2003; 170:4465-74; PMID:12707322.
123. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005; 23:457-62; PMID:15778705; http://dx.doi.org/10.1038/nbt1081.
124. Forsbach A, Nemorin JG, Montino C, Müller C, Samulowitz U, Vicari AP, et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol 2008; 180:3729-38; PMID:18322178.
125. Ablasser A, Poeck H, Anz D, Berger M, Schlee M, Kim S, et al. Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. J Immunol 2009; 182:6824-33; PMID:19454678; http://dx.doi.org/10.4049/jimmunol. 0803001.
126. Scheel B, Braedel S, Probst J, Carralot JP, Wagner H, Schild H, et al. Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol 2004; 34:537-47; PMID:14768059; http://dx.doi.org/10.1002/eji.200324198.
127. Scheel B, Aulwurm S, Probst J, Stitz L, Hoerr I, Rammensee HG, et al. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur J Immunol 2006; 36:2807-16; PMID:17013976; http://dx.doi.org/10.1002/eji.200635910.
128. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13:552-9; PMID:17479101; http://dx.doi.org/10.1038/nm1589.
129. Barchet W, Wimmenauer V, Schlee M, Hartmann G. Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr Opin Immunol 2008; 20:389-95; PMID:18652893; http://dx.doi.org/10.1016/j.coi.2008.07.007.
130. Lan T, Kandimalla ER, Yu D, Bhagat L, Li Y, Wang D, et al. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. Proc Natl Acad Sci USA 2007; 104:13750-5; PMID:17698957; http://dx.doi.org/10.1073/ pnas.0706059104.
131. Sugiyama T, Gursel M, Takeshita F, Coban C, Conover J, Kaisho T, et al. CpG RNA: identification of novel single-stranded RNA that stimulates human CD14+CD11c+ monocytes. J Immunol 2005; 174:2273-9; PMID:15699162.
132. Kerkmann M, Costa LT, Richter C, Rothenfusser S, Battiany J, Hornung V, et al. Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferonalpha induction by CpG-A in plasmacytoid dendritic cells. J Biol Chem 2005; 280:8086-93; PMID:15591070; http://dx.doi.org/10.1074/jbc. M410868200.
133. Heidel JD, Hu S, Liu XF, Triche TJ, Davis ME. Lack of interferon response in animals to naked siRNAs. Nat Biotechnol 2004; 22:1579-82; PMID:15558046; http://dx.doi.org/10.1038/nbt1038.
134. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003; 34:263-4; PMID:12796781; http://dx.doi.org/10.1038/ng1173.
135. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5:834-9; PMID:12942087; http://dx.doi.org/10.1038/ncb1038.
136. Marques JT, Williams BR. Activation of the mammalian immune system by siRNAs. Nat Biotechnol 2005; 23:1399-405; PMID:16273073; http://dx.doi.org/10. 1038/nbt1161.
137. Persengiev SP, Zhu X, Green MR. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 2004; 10:12-8; PMID:14681580; http://dx.doi.org/10.1261/ rna5160904.
138. Karikó K, Bhuyan P, Capodici J, Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol 2004; 172:6545-9; PMID:15153468.
139. Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 2005; 348:1079-90; PMID:15854645; http://dx.doi.org/10.1016/j.jmb.2005.03.013.
140. Sioud M. Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2′-hydroxyl uridines in immune responses. Eur J Immunol 2006; 36:1222-30; PMID:16609928; http://dx.doi.org/10.1002/eji.200535708.
141. Masquida B, Westhof E. On the wobble GoU and related pairs. RNA 2000; 6:9-15; PMID:10668794; http://dx.doi.org/10.1017/S1355838200992082.
142. Sioud M. Innate sensing of self and non-self RNAs by Toll-like receptors. Trends Mol Med 2006; 12:167-76; PMID:16530484; http://dx.doi.org/10.1016/j. molmed.2006.02.004.
143. Marques JT, Devosse T, Wang D, Zamanian-Daryoush M, Serbinowski P, Hartmann R, et al. A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol 2006; 24:559-65; PMID:16648842; http://dx.doi.org/10.1038/nbt1205.
144. Cekaite L, Furset G, Hovig E, Sioud M. Gene expression analysis in blood cells in response to unmodified and 2′-modified siRNAs reveals TLR-dependent and independent effects. J Mol Biol 2007; 365:90-108; PMID:17054988; http://dx.doi.org/10.1016/j.jmb.2006.09.034.
145. Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS, et al. 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 2008; 14:1256-63; PMID:18978796; http://dx.doi.org/10.1038/ nm.1887.
146. Khairuddin N, Gantier MP, Blake SJ, Wu SY, Behlke MA, Williams BR, et al. siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol Cell Biol 2012; 90:187-96; PMID:21423261; http://dx.doi.org/10.1038/icb.2011.19.
147. Furset G, Sioud M. Design of bifunctional siRNAs: combining immunostimulation and gene-silencing in one single siRNA molecule. Biochem Biophys Res Commun 2007; 352:642-9; PMID:17150189; http://dx.doi.org/10.1016/j. bbrc.2006.11.059.
148. Gantier MP, Tong S, Behlke MA, Irving AT, Lappas M, Nilsson UW, et al. Rational design of immunostimulatory siRNAs. Mol Ther 2010; 18:785-95; PMID:20125126; http://dx.doi.org/10.1038/mt.2010.4.
149. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441:111-4; PMID:16565705; http://dx.doi.org/10.1038/nature04688.
150. Hamm S, Latz E, Hangel D, Müller T, Yu P, Golenbock D, et al. Alternating 2′-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist. Immunobiology 2010; 215:559-69; PMID:19854535; http://dx.doi.org/10.1016/j.imbio.2009.09.003.
151. Strumberg D, Schultheis B, Traugott U, Vank C, Santel A, Keil O, et al. Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther 2012; 50:76-8; PMID:22192654.
152. Amarzguioui M, Holen T, Babaie E, Prydz H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 2003; 31:589-95; PMID:12527766; http://dx.doi.org/10.1093/nar/gkg147.
153. Braasch DA, Jensen S, Liu Y, Kaur K, Arar K, White MA, et al. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 2003; 42:7967-75; PMID:12834349; http://dx.doi.org/10.1021/bi0343774.
154. Sioud M. Does the understanding of immune activation by RNA predict the design of safe siRNAs? Front Biosci 2008; 13:4379-92; PMID:18508517; http://dx.doi.org/10.2741/3011.
155. Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 2006; 13:494-505; PMID:16343994; http://dx.doi.org/10.1016/j.ymthe.2005.11.002.
156. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008; 8:594-606; PMID:18641647; http://dx.doi.org/10.1038/nri2358.
157. Krug A, Luker GD, Barchet W, Leib DA, Akira S, Colonna M. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood 2004; 103:1433-7; PMID:14563635; http://dx.doi.org/10.1182/blood-2003-08-2674.
158. Krug A, French AR, Barchet W, Fischer JA, Dzionek A, Pingel JT, et al. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 2004; 21:107-19; PMID:15345224; http://dx.doi.org/10.1016/j.immuni.2004.06.007.
159. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med 2003; 198:513-20; PMID:12900525; http://dx.doi.org/10.1084/jem. 20030162.
160. Hokeness-Antonelli KL, Crane MJ, Dragoi AM, Chu WM, Salazar-Mather TP. IFNalphabeta-mediated inflammatory responses and antiviral defense in liver is TLR9-independent but MyD88-dependent during murine cytomegalovirus infection. J Immunol 2007; 179:6176-83; PMID:17947693.
161. Zhang SY, Jouanguy E, Ugolini S, Smahi A, Elain G, Romero P, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007; 317:1522-7; PMID:17872438; http://dx.doi.org/10.1126/science.1139522.
162. Yang K, Puel A, Zhang S, Eidenschenk C, Ku CL, Casrouge A, et al. Human TLR-7-, -8- and -9-mediated induction of IFNalpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity 2005; 23:465-78; PMID:16286015; http://dx.doi.org/10.1016/j.immuni.2005.09.016.
163. Ku CL, von Bernuth H, Picard C, Zhang SY, Chang HH, Yang K, et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 2007; 204:2407-22; PMID:17893200; http://dx.doi.org/10.1084/jem.20070628.
164. Brinkmann MM, Spooner E, Hoebe K, Beutler B, Ploegh HL, Kim YM. The interaction between the ER membrane protein UNC93B and TLR3, 7 and 9 is crucial for TLR signaling. J Cell Biol 2007; 177:265-75; PMID:17452530; http://dx.doi.org/10.1083/jcb.200612056.
165. Fukui R, Saitoh S, Kanno A, Onji M, Shibata T, Ito A, et al. Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking. Immunity 2011; 35:69-81; PMID:21683627; http://dx.doi.org/10. 1016/j.immuni.2011.05.010.
166. Gratz N, Hartweger H, Matt U, Kratochvill F, Janos M, Sigel S, et al. Type I interferon production induced by Streptococcus pyogenes-derived nucleic acids is required for host protection. PLoS Pathog 2011; 7:1001345; PMID:21625574; http://dx.doi.org/10.1371/journal.ppat.1001345.
167. Bourgeois C, Majer O, Frohner IE, Lesiak-Markowicz I, Hildering KS, Glaser W, et al. Conventional dendritic cells mount a type I IFN response against Candida spp requiring novel phagosomal TLR7-mediated IFN-β signaling. J Immunol 2011; 186:3104-12; PMID:21282509; http://dx.doi.org/10. 4049/jimmunol.1002599.
168. Biondo C, Signorino G, Costa A, Midiri A, Gerace E, Galbo R, et al. Recognition of yeast nucleic acids triggers a host-protective type I interferon response. Eur J Immunol 2011; 41:1969-79; PMID:21480215; http://dx.doi.org/10. 1002/eji.201141490.
169. Lee J, Wu CC, Lee KJ, Chuang TH, Katakura K, Liu YT, et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci USA 2006; 103:1828-33; PMID:16446426; http://dx.doi.org/10.1073/pnas.0510801103.
170. Franklin BS, Ishizaka ST, Lamphier M, Gusovsky F, Hansen H, Rose J, et al. Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria. Proc Natl Acad Sci USA 2011; 108:3689-94; PMID:21303985; http://dx.doi.org/10.1073/pnas.1015406108.
171. Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity 2003; 19:837-47; PMID:14670301; http://dx.doi.org/10.1016/S1074-7613(03)00323-6.
172. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007; 13:543-51; PMID:17479100; http://dx.doi.org/10.1038/ nm1590.
173. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005; 202:1171-7; PMID:16260486; http://dx.doi.org/10.1084/jem.20050630.
174. Lövgren T, Eloranta ML, Båve U, Alm GV, Rönnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004; 50:1861-72; PMID:15188363; http://dx.doi.org/10.1002/art.20254.
175. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449:564-9; PMID:17873860; http://dx.doi.org/10.1038/ nature06116.
176. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferonalpha production. J Exp Med 2005; 202:135-43; PMID:15998792; http://dx.doi.org/10. 1084/jem.20050500.
177. Vollmer J, Tluk S, Schmitz C, Hamm S, Jurk M, Forsbach A, et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005; 202:1575-85; PMID:16330816; http://dx.doi.org/10.1084/jem.20051696.
178. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6:823-35; PMID:17063184; http://dx.doi.org/10.1038/ nri1957.
179. Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006; 312:1669-72; PMID:16709748; http://dx.doi.org/ 10.1126/science.1124978.
180. Deane JA, Pisitkun P, Barrett RS, Feigenbaum L, Town T, Ward JM, et al. Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 2007; 27:801-10; PMID:17997333; http://dx.doi.org/10.1016/j.immuni.2007.09.009.
181. Berland R, Fernandez L, Kari E, Han JH, Lomakin I, Akira S, et al. Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity 2006; 25:429-40; PMID:16973388; http://dx.doi.org/10.1016/j.immuni.2006.07.014.
182. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006; 25:417-28; PMID:16973389; http://dx.doi.org/10.1016/j.immuni.2006.07.013.
183. Lee PY, Kumagai Y, Li Y, Takeuchi O, Yoshida H, Weinstein J, et al. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J Exp Med 2008; 205:2995-3006; PMID:19047436; http://dx.doi.org/10.1084/jem.20080462.
184. Lang KS, Recher M, Junt T, Navarini AA, Harris NL, Freigang S, et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 2005; 11:138-45; PMID:15654326; http://dx.doi.org/ 10.1038/nm1176.
185. Lang KS, Georgiev P, Recher M, Navarini AA, Bergthaler A, Heikenwalder M, et al. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J Clin Invest 2006; 116:2456-63; PMID:16955143; http://dx.doi.org/10.1172/JCI28349.
186. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005; 52:2656-65; PMID:16142732; http://dx.doi.org/10.1002/art.21273.
187. Isnardi I, Ng YS, Srdanovic I, Motaghedi R, Rudchenko S, von Bernuth H, et al. IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 2008; 29:746-57; PMID:19006693; http://dx.doi.org/10.1016/j.immuni.2008.09.015.
188. Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010; 465:937-41; PMID:20559388; http://dx.doi.org/10.1038/nature09102.
189. Chen SY, Shiau AL, Li YT, Lin YS, Lee CH, Wu CL, et al. Suppression of collagen-induced arthritis by intra-articular lentiviral vector-mediated delivery of Toll-like receptor 7 short hairpin RNA gene. Gene Ther 2011; PMID:22089492; http://dx.doi.org/10.1038/gt.2011.173.